KemPharm Inc (1GDA.MU)
| Previous close | 4.7400 |
| Open | 4.7400 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 4.7400 - 4.7400 |
| 52-week range | 3.9200 - 6.4500 |
| Volume | |
| Avg. volume | 32 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript May 8, 2024 Zevra Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics’ First Quarter 2024 Corporate Update and Financial […]
GlobeNewswireZevra Therapeutics to Participate at Upcoming Investor Events
CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at several upcoming investor events in May 2024. Additionally, management will be available for one-on-one meetings with registered attendees. Mr. McFarlane will present at The Citizens JMP Life Sciences Conference in New York, NY, on Tuesday,
Simply Wall St.Zevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zevra Therapeutics ( NASDAQ:ZVRA ) First Quarter 2024 Results Key Financial Results Revenue: US$3.43m (up 19% from 1Q...
